User:Pradaxacost

The effectiveness of pradaxa value was studied in two randomized, double-blind, parallel group trials involving almost 5600 patients undergoing knee or hip replacement surgery. The sufferers received 150 or 220 mg dabigatran etexilate when day-to-day orally or 40 mg enoxaparin subcutaneously. The main endpoint was the mixture of just about every on the total quantity of venous thromboembolism (VTE) and total mortality, a secondary endpoint was the composite of big VTE and VTE-related mortality. [3] In the two research, dabigatran etexilate as efficient as enoxaparin with respect to the prevention of clot formation or to avoid death: